课题基金 / 基金详情

Comparative effectiveness in genomic & personalized medicine for colon cancer

Comparative effectiveness in genomic & personalized medicine for colon cancer
基因组有效性比较
批准号:
7944121
负责人:
KATRINA A. GODDARD
金额:
$199.18万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-29 至 2012-08-31

项目摘要

项目成果

KATRINA A. GODDARD的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):近年来,基因组或其他分子检测已被推荐用于癌症治疗领域的临床实践。它们用于识别高危个体,筛选并进行早期检测,确定预后标记物,并指导治疗过程。我们提出了一个重点研究项目,将调查几种与结直肠癌相关的测试的比较有效性。这项拟议的研究是由nci资助的癌症研究网络(CRN)的几个成员网站和学术伙伴合作进行的。
英文摘要
DESCRIPTION (Provided by the applicant): In recent years, genomic or other molecular tests have been recommended for clinical practice in the area of cancer treatment. They are used to identify individuals at high risk, screen and perform early detection, identify prognostic markers, and guide course of therapy. We propose a focused program of research that will investigate the comparative effectiveness of several tests related to colorectal cancer. The proposed study is a collaboration of several of the member sites of the NCI-funded Cancer Research Network (CRN) and academic partners. Our comprehensive research program in GPM for colorectal cancer will have two main components: 1) secondary data collection through evidence synthesis and cost-effectiveness analysis, and 2) primary data collection through a proof-of-principle study to examine questions about personalized medicine for colorectal cancer. In the proof-of-principle study, we will evaluate the utilization of KRAS and Lynch Syndrome genetic tests within our health systems, and measure the effectiveness of KRAS testing compared with a patient population that does not receive testing. We will also conduct patient and physician interviews to measure psychosocial issues related to KRAS testing, and to help us understand how the genetic test results are used to inform decisions. Our research program in colorectal cancer will build the experience, data systems, and methods that can apply to other cancer-related genetic or molecular tests in the future, such as UGT1A1 testing, or Oncotype DX and CYP2D6 testing for breast cancer. The interwoven research program that we propose will provide opportunities for synergy between teams of researchers conducting primary and secondary data collection. PUBLIC HEALTH RELEVANCE: We will study several genetic tests related to colon cancer that may help doctors understand who will get colon cancer and what therapies some patients should receive. We will study who gets tested, how the genetic test result helps people decide what to do, and whether patients have different health outcomes when they get tested. We will also summarize research that has already been published and analyze cost information about the use of these tests.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exome sequencing in Diverse Populations in Colorado & Oregon
Exome sequencing in Diverse Populations in Colorado & Oregon
Clinical Implementation of Carrier Testing using NGS
Barriers to Knowledge of Family History and Family Communication among Sexual Minorities and the Implications in the Context of Hereditary Cancer Syndromes
海外基金